Cargando…

Mucormycosis in Mainland China: A Systematic Review of Case Reports

BACKGROUND: Mucormycosis is a lethal fungal infection with increasing incidence. The epidemiology of mucormycosis in current mainland China has not been fully elucidated. OBJECTIVES: To investigate the epidemiology, risk factors, manifestations, diagnosis, treatment and prognosis of mucormycosis in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Lin-Wei, Zhu, Pei-Qiu, Chen, Xiao-Qing, Yu, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637510/
https://www.ncbi.nlm.nih.gov/pubmed/34855101
http://dx.doi.org/10.1007/s11046-021-00607-4
_version_ 1784608754713493504
author Wei, Lin-Wei
Zhu, Pei-Qiu
Chen, Xiao-Qing
Yu, Jin
author_facet Wei, Lin-Wei
Zhu, Pei-Qiu
Chen, Xiao-Qing
Yu, Jin
author_sort Wei, Lin-Wei
collection PubMed
description BACKGROUND: Mucormycosis is a lethal fungal infection with increasing incidence. The epidemiology of mucormycosis in current mainland China has not been fully elucidated. OBJECTIVES: To investigate the epidemiology, risk factors, manifestations, diagnosis, treatment and prognosis of mucormycosis in mainland China. METHODS: We searched for published mucormycosis case reports/series in mainland China in the PubMed, WanFang and China National Knowledge Infrastructure databases from January 2001 to July 2020. Cases of proven/probable mucormycosis were included. RESULTS: A total of 390 cases were included in this review. Most of the patients were male (61.3%), and diabetes was the most common predisposing factor (37.2%). Pulmonary mucormycosis (42.1%) was the most common form followed by cutaneous infection (21.0%). Of 390 patients, 24 died before therapy. Among the remaining 366 patients, 208 (56.8%) received antifungal drugs alone, 16 (4.4%) received surgery alone, and 142 (38.8%) received a combination of drugs and surgery, the mortality of the last group is much lower (34/142, 23.9%). The overall mortality was 37.2%. A multivariate analysis indicated that factors associated with increased mortality included corticosteroid use alone as immunosuppressive therapy, rhino-orbito-cerebral or disseminated mucormycosis (compared with pulmonary mucormycosis), and drug administration other than amphotericin B (AmB), posaconazole (POS) and itraconazole (ITR) (compared with the use of conventional AmB), while factors associated with decreased mortality included cutaneous mucormycosis and surgical therapy. Combination or sequential antifungal therapy of AmB and POS or ITR did not reduce mortality compared with conventional AmB monotherapy. CONCLUSION: In mainland China, mucormycosis is a serious fungal infection with high mortality. Corticosteroid use, rhino-orbito-cerebral and disseminated mucormycosis were adverse prognostic factors. Antifungal therapy combined with surgery could improve the prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11046-021-00607-4.
format Online
Article
Text
id pubmed-8637510
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-86375102021-12-02 Mucormycosis in Mainland China: A Systematic Review of Case Reports Wei, Lin-Wei Zhu, Pei-Qiu Chen, Xiao-Qing Yu, Jin Mycopathologia Original Article BACKGROUND: Mucormycosis is a lethal fungal infection with increasing incidence. The epidemiology of mucormycosis in current mainland China has not been fully elucidated. OBJECTIVES: To investigate the epidemiology, risk factors, manifestations, diagnosis, treatment and prognosis of mucormycosis in mainland China. METHODS: We searched for published mucormycosis case reports/series in mainland China in the PubMed, WanFang and China National Knowledge Infrastructure databases from January 2001 to July 2020. Cases of proven/probable mucormycosis were included. RESULTS: A total of 390 cases were included in this review. Most of the patients were male (61.3%), and diabetes was the most common predisposing factor (37.2%). Pulmonary mucormycosis (42.1%) was the most common form followed by cutaneous infection (21.0%). Of 390 patients, 24 died before therapy. Among the remaining 366 patients, 208 (56.8%) received antifungal drugs alone, 16 (4.4%) received surgery alone, and 142 (38.8%) received a combination of drugs and surgery, the mortality of the last group is much lower (34/142, 23.9%). The overall mortality was 37.2%. A multivariate analysis indicated that factors associated with increased mortality included corticosteroid use alone as immunosuppressive therapy, rhino-orbito-cerebral or disseminated mucormycosis (compared with pulmonary mucormycosis), and drug administration other than amphotericin B (AmB), posaconazole (POS) and itraconazole (ITR) (compared with the use of conventional AmB), while factors associated with decreased mortality included cutaneous mucormycosis and surgical therapy. Combination or sequential antifungal therapy of AmB and POS or ITR did not reduce mortality compared with conventional AmB monotherapy. CONCLUSION: In mainland China, mucormycosis is a serious fungal infection with high mortality. Corticosteroid use, rhino-orbito-cerebral and disseminated mucormycosis were adverse prognostic factors. Antifungal therapy combined with surgery could improve the prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11046-021-00607-4. Springer Netherlands 2021-12-02 2022 /pmc/articles/PMC8637510/ /pubmed/34855101 http://dx.doi.org/10.1007/s11046-021-00607-4 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Wei, Lin-Wei
Zhu, Pei-Qiu
Chen, Xiao-Qing
Yu, Jin
Mucormycosis in Mainland China: A Systematic Review of Case Reports
title Mucormycosis in Mainland China: A Systematic Review of Case Reports
title_full Mucormycosis in Mainland China: A Systematic Review of Case Reports
title_fullStr Mucormycosis in Mainland China: A Systematic Review of Case Reports
title_full_unstemmed Mucormycosis in Mainland China: A Systematic Review of Case Reports
title_short Mucormycosis in Mainland China: A Systematic Review of Case Reports
title_sort mucormycosis in mainland china: a systematic review of case reports
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637510/
https://www.ncbi.nlm.nih.gov/pubmed/34855101
http://dx.doi.org/10.1007/s11046-021-00607-4
work_keys_str_mv AT weilinwei mucormycosisinmainlandchinaasystematicreviewofcasereports
AT zhupeiqiu mucormycosisinmainlandchinaasystematicreviewofcasereports
AT chenxiaoqing mucormycosisinmainlandchinaasystematicreviewofcasereports
AT yujin mucormycosisinmainlandchinaasystematicreviewofcasereports